GlassScriptPhysician profile
Mamatha G Mohan
NPI 1710016761
$7,735.25
in general payments reported to CMS, 2019-2025
40 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $458 · 2021: $1,040 · 2022: $1,439 · 2023: $1,368 · 2024: $1,621 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,209.99 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,125.80 | 2020-2025 | Farxiga, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $813.60 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $811.23 | 2021-2025 | |
| Amgen INC. | $458.60 | 2020-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $391.60 | 2022-2025 | Verquvo, Steglatro, Belsomra |
| Insulet Corporation | $303.23 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $301.57 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $300.01 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $283.64 | 2024 | Freestyle Libre 3, Mitraclip |
| Idorsia Pharmaceuticals US INC | $230.88 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $218.69 | 2021-2025 | |
| Amarin Pharma, INC. | $211.61 | 2020-2021 | |
| Cvrx, INC. | $174.89 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.07 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamatha Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.